Expression Of miR-155 In Patients Research Articles

Correlation of miR-155-5p, KRAS, and CREB Expression in Patients with Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a type of blood cancer involving numerous aberrant genes and microRNAs. MiRNAs are non-coding sequences that have been proven to be players in the biological processes of various cancers. The present study is designed to illustrate the relationship between miR-155, KRAS, and CREB. This case-control study was conducted on 21 patients with AML and 9 healthy individuals. The expressions of miR-155, KRAS, and CREB were measured using RT-PCR. Demographic data were extracted from the documents of individuals. SPSS and GraphPad Prism software were used to analyze the data. The expression of miR-155 in patients with AML was 35 times higher than in the control group (p < 0.0001). Also, CREB fold change increased by 1.92-fold in patients compared to the controls (p = 0.034), but no difference in KRAS was observed between the control and AML groups (p > 0.05). There was no change in miR-155, CREB, and KRAS expression based on gender, age, and blast percentage (p > 0.5). Nevertheless, there was a direct correlation between CREB and KRAS expressions (p = 0.0002). Our result showed that overexpression of CREB and KRAS would cause an increase in white blood cells (WBCs) (p = 0.001, 0.045 respectively), but there was no correlation between miR-155 with WBCs (p > 0.5). Our study revealed that miR-155 and CREB had overexpression compared to the control group.

Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients

Abstract Background Chemotherapy-induced cardiomyopathy (CIC) is a common side effect affecting patients with breast cancer treated with anthracyclines chemotherapeutic agents. Vitamin D receptor gene polymorphism seemed to play a crucial role in developing CIC, as vitamin D deficiency was found to increase the risk of many diseases including colon, breast, prostate and ovarian cancer. Purpose The current study is primarily to investigate the effect of vitamin D receptor gene polymorphism (ApaI, TaqI, BsmI and FokI) on the incidence of CIC in adult patients with local/advanced or metastatic breast cancer on anthracyclines. Another aim is to detect the association of the gene polymorphism with the response to treatment with chemotherapeutic agents. Moreover, the current study investigated the expression of miR-155 in patients and analyzed its relationship with CIC occurrence. Methods This case-control study recruited 60 breast cancer patients with CIC and 30 breast cancer patients without CIC from cardiology and oncology clinics between February 2017 and November 2021. Genomic DNA was extracted from peripheral blood samples and VDR gene polymorphisms were detected using TaqMan techniques. Results For the ApaI (rs7975232) and TaqI (rs731236) single-nucleotide polymorphisms (SNPs), the heterozygous (CA) and heterozygous (GA) genotypes increased the risk of CIC among breast cancer patients compared to the control group (OR = 4.31, P &amp;lt; 0.001; OR = 3.2, P = 0.015, respectively). In contrast, homozygous (CC) carriers of the BsmI SNP (rs1544410) had a significantly lower risk for CIC among breast cancer patients (P &amp;lt; 0.001). Finally, for the FokI SNP (rs2228570), there was no significant association with CIC risk. Levels of miR-155 were significantly increased in CIC group compared to the control group (P = 0.015). Conclusion The C allele carriers of ApaI SNP and A allele carriers of TaqI SNP are at higher risk of CIC among breast cancer patients; in contrast, the homozygous (CC) carriers of the BsmI SNP are protective against CIC among breast cancer patients. Additionally, higher levels of miR-155 are associated with CIC increased risk among breast cancer patients.

Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling

Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibition in the bile duct ligation (BDL) mouse model of liver fibrosis and evaluated the role of miR-155 in chronic liver fibrosis using miR-155-deficient (miR-155 knockout [KO]) mice. We found increased hepatic miR-155 expression in patients with cirrhosis and in the BDL- and CCl4-induced mouse models of liver fibrosis. Liver fibrosis was significantly reduced in miR-155 KO mice after CCl4 administration or BDL. To assess the therapeutic potential of miR-155 inhibition, we administered an rAAV8-anti-miR-155 tough decoy invivo that significantly reduced liver damage and fibrosis in BDL. BDL-induced protein levels of transforming growth factor β (TGF-β), p-SMAD2/3, and p-STAT3 were attenuated in anti-miR-155-treated compared with control mice. Hepatic stellate cells from miR-155 KO mice showed attenuation in activation and mesenchymal marker expression. Invitro, miR-155 gain- and loss-of-function studies revealed that miR-155 regulates activation of stellate cells partly via STAT3 signaling. Our study suggests that miR-155 is the key regulator of liver fibrosis and might be a potential therapeutic target to attenuate fibrosis progression.

Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study.

Non-Hodgkin lymphoma (NHL) is the eleventh leading cause of cancer-related death in the world. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL. Up to winter 2021-2022, the death toll caused by the coronavirus disease 2019 (COVID-19) has exceeded 5.6 million worldwide. Possible molecular mechanisms involved in the systemic inflammation, and cytokine storm in COVID-19 patients are still not fully understood. MicroRNA-155 (miR-155) plays a role in the post-transcriptional gene regulation of hematopoiesis, oncogenesis, and inflammation. The present study aimed to evaluate the expression of miR-155 in patients with DLBCL and/or COVID-19. A cross-sectional study was conducted from July to December 2020 in Tehran (Iran) to evaluate the expression of miR-155 in adult patients diagnosed with DLBCL and/or COVID-19. The real-time polymerase chain reaction technique was used to evaluate the expression of miR-155 in the sera of 92 adults who were either healthy or suffering from DLBCL and/or COVID-19. Relative quantification of gene expression was calculated in terms of cycle threshold (Ct) value. Data were analyzed using SPSS software, and P<0.05 was considered statistically significant. The expression of miR-155 was not associated with the sex or age of the participants. In comparison with healthy individuals (-ΔCt -1.92±0.25), the expression of miR-155 increased in patients with COVID-19 (1.95±0.14), DLBCL (2.25±0.16), or both (4.33±0.65). The expression of miR-155 increased in patients with DLBCL and/or COVID-19.

Circ 0006282/miR-155 reduced inflammation in diabetic nephropathy via expression of SIRT1/NLRP3 signaling pathway

Abstract This study aimed to explore the effects and mechanism of circ 0006282 in Diabetic nephropathy (DN) in vitro and in vivo. 6-week-old male db/db mice were induced by intraperitoneal (I.P) injection of STZ (50 mg/kg, S0130, Sigma, St. Louis, MO, USA) for five consecutive days. HK-2 cells was incubated with high glucose for vitro model. Western blotting, immunostaining, and biochemical assays were used to obtain that inflammatory factor and protein expressions. The current study demonstrated that the serum circ 0006282 expression were reduced, and serum miR-155 expression in patients with DN were increased. Circ 0006282 reduced inflammation in kidney cell by high glucose. MiR-155 promoted inflammation in kidney cell by high glucose. Circ 0006282 reduced inflammation via activation of SIRT1/NLRP3 signaling pathway by suppression of miR-155 expression. MiR-155 regulated the anti-inflammation effects of circ 0006282 on inflammation in kidney cell by high glucose by SIRT1/NLRP3 signaling pathway. Taken together, these results suggest that circ 0006282 may represent promising strategy for the therapy of DN.

Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma

To investigate the relationship between the polymorphism of miR-155 and its target gene MyD88 and clinicopathological features of diffuse large B-cell lymphoma (DLBCL). 135 cases of DLBCL patients in our hospital from March 2015 to August 2017 were selected, and 90 cases of reactive hyperplasia of lymph nodes were selected as the control group. The relative expression of miR-155 and MyD88 gene polymorphism were detected in the two groups, and the relationship between miR-155 and MyD88 gene polymorphism and clinicopathological characteristics of DLBCL was analyzed. The relative expression of miR-155 in DLBCL patients was significantly higher than that in the control group (P<0.05). The mutation rate of MyD88 L265P in DLBCL group was significantly higher than that in control group (P<0.05). The relative expression of miR-155 in patients with MyD88 L265P mutation was significantly higher than that in patients with wild-type DLBCL (P<0.05). The relative expression of miR-155 and the polymorphism of MyD88 L265P were associated with lesion location, stage, BCL-2 protein expression and MyD88 protein expression in DLBCL patients (t=7.461、8.804、6.487、10.812； χ2=10.681、8.599、7.251、23.008；P<0.05). The survival of DLBCL patients with low miR-155 expression was significantly better than that with high miR-155 expression (P<0.05). The survival of wild-type DLBCL patients with MyD88 L265P locus was significantly better than that of mutant DLBCL patients (P<0.05). There was a significant positive correlation between the relative expression of miR-155 and the expression of MyD88 protein (r=0.428, P=0.000). The abnormal expression of miR-155 and the mutation rate of MyD88 gene in DLBCL patients are increased, and the expression of miR-155 and the mutation of MyD88 gene affect the disease progression and prognosis of patients, which may be potential biological indicators for the diagnosis, treatment and prognosis of DLBCL.

Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer.

Aim Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient's serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software. Results The mean age of subjects in breast cancer and control groups was 47.64 ± 8.19 and 47.36 ± 7.52 years, respectively. The serum miR-155 expression was higher in the cancer group (1.68 ± 0.66) compared to the control group (p < 0.0001). There was a significant relationship between serum miR-155 expression and the tumor grade (p < 0.001), tumor stage (p < 0.001), and tumor size (p < 0.001) of the patients. However, no relationship between miR-155 expression and the presence of lymph node involvement (p = 0.15), HER2 (p = 0.79), Ki-67 (p = 0.9), progesterone receptor (p = 0.54), and estrogen receptors (p = 0.84) was found. The ROC curve analysis showed that the AUC was 0.89 (77.78% sensitivity and 88.89% specificity), and the cutoff was 1.4 (Youden index: 0.6667) for detecting breast cancer. Conclusion The findings of this study revealed that serum miR-155 may serve as a potential noninvasive molecular biomarker for breast cancer diagnosis and can help predict the grade of the disease.

MiR-155 expression is a potential biomarker of systemic lupus erythematosus diagnosis and disease activity prediction

BackgroundEarly diagnosis of Systemic Lupus Erythematosus (SLE) and its activity has a curtail role in the proper management of the disease with positive effect on its prognosis. MicroRNAs (miRNAs) evidently take apart in the pathogenesis of autoimmune diseases. Many miRNAs play a role in SLE pathogenesis and miR-155 is one of them. ObjectiveTo examine miR-155 expression in patients with SLE and evaluate its role in the disease development and activity. Subjects and methodsThe current study evaluated miR-155 expression in 60 SLE patients and 40 apparently healthy controls (HCs) using real-time polymerase chain reaction. Diagnosis was according to Systemic Lupus International Collaborating Clinics (SLICC) criteria. Disease activity was evaluated by systemic lupus erythematosus disease activity index (SLEDAI-2 K) score. ResultsmiR-155 level was significantly higher in SLE patients than controls with significant positive correlation with SLEDAI score and positive relation to renal involvement, proteinuria, pulmonary complications, fever and dsDNA antibodies. Multivariate regression analysis revealed that miR-155 is a significant risk factor for SLE. ConclusionOverexpression of miR-155 occurs in SLE and it can be used as a predictor biomarker for disease's development and activity. It also may be a risk for renal involvement in the disease course.

Optimization of complex diagnosis and treatment of patients with psoriasis on the background of herpes virus infection of types 1, 2

Objective — improving the diagnosis, increasing the effectiveness and evaluation of safety of antiviral therapy in the complex treatment of patients with psoriasis (P) and activated chronic herpes virus infection of type 1, 2 (HSV 1, 2) taking into account the molecular, genetic, and immunological mechanisms of these diseases, development of approaches to predicting the course of dermatosis.Materials and methods. To achieve this purpose and solve the relevant tasks during 2017—2020, we examined 120 patients with clinical, general laboratory, biochemical, molecular, genetic, and immunological methods.Results and discussion. In patients with P + HSV 1, 2, a higher (by 2.1 times; p < 0.05) level of miR-155 expression was determined compared to that in patients with activated HSV 1, 2 only, and miR-146a expression was 1.8 times lower (p < 0.05) compared with the index in patients with P. A direct relationship was established between the number of lymphocytes and miR-155 expression in patients with P + HSV 1, 2 (r = 0.46; p < 0.05). After complex therapy with antiviral drugs, miR-155 expression in patients with P + HSV 1, 2 was reduced, especially compared with the group of patients who received basic therapy (p < 0.05).In patients with P + HSV 1, 2, an increased number of regulatory T-lymphocytes was detected compared to that in patients with P (p < 0.05). At the same time, the number of T-helpers in these two groups was greater (p < 0.01) compared with that in healthy individuals. Conducted antiviral treatment led to an increase in the number of regulatory cells (p = 0.0503) after treatment and compared to the patients who received only basic therapy (p = 0.0122). Relationships were improved between B-lymphocytes and T-regulatory cells (r = 0.41; p < 0.05), between T-helpers and T-cytotoxic lymphocytes (r = –0.51; p < 0.05).Patients with P + HSV 1, 2 had a 3.5 times increase in the level of IFN-a in the blood compared to healthy people and 2.8 times increase in the same index compared to patients with P; IL-23 in the blood was 2.6 times higher than in the healthy persons and 1.9 times higher than in patients with activated HSV 1, 2; the level of TGF-b in the blood was decreased by 1.9 times compared to that of healthy persons and by 2.1 times compared to patients with activated HSV 1, 2. The use of antiviral drugs in the complex treatment of patients with P + HSV 1, 2 showed a decrease in the synthesis of IFN in saliva (p = 0.0398) and IL-23 (p = 0.0278) in the blood, as well as an increase in the level of TGF-b (p = 0.0438).Conclusions. An improved method of treatment and assessment of its clinical and immunological effectiveness on the basis of an integrated scale for patients with P + HSV 1, 2 are proposed, which provides for the use of inosine pranobex and/or acyclovir depending on the severity of HSV 1, 2 against the background of standard therapy for 90 days. This promotes higher effectiveness of the treatment of such patients compared with those receiving only basic therapy.

Expression and Prognostic Value of MiR-155 in Patients with Chronic Lymphocytic Leukemia

To explore the expression of miR-155 in patients with chronic lymphocytic leukemia (CLL) and its correlation with the clinical and biological features in CLL. The expression of miR-155 was detected by quantitative real time polymerase chain reaction (qRT-PCR) in the peripheral mononuclear cells collected from 73 CLL patients and CD19 positive B cells collected from 60 healthy controls, respectively. The expression of miR-155 in CLL patients was compared with the healthy controls, and the correlation of miR-155 expression with the clinical characteristics of CLL patients such as age, sex, Binet stage, cytogenetic and molecular genetic, as well as the relationship of miR-155 expression level with time to treatment (TTT) and overall survival (OS) was further analysed. The expression of miR-155 was significantly elevated in CLL patients compared with the healthy controls. Further analysis showed that miR-155 expression decreased in the patients with the mutated immunoglobulin heavy chian variable region (IGHV) as compared with the patients unmutated (P＜0.05), and its expression was significant higher in the IGHV-39 family (P＜0.05). Fluorescence in situ hybridization (FISH) showed that the expression of miR-155 increased in patients with P53 mmutation/deletion and ATM deletion (P＜0.05). However, OS and TTT were not different between the patients with high and low expression of miR-155. MiR-155 is increasingly expresses in CLL patients and correlates with poor prognosis, suggesting its important role in the genesis and progress of CLL.

Expression and Prognostic Value of MiR-155 in Patients with Chronic Lymphocytic Leukemia

To explore the expression of miR-155 in patients with chronic lymphocytic leukemia (CLL) and its correlation with the clinical and biological features in CLL. The expression of miR-155 was detected by quantitative real time polymerase chain reaction (qRT-PCR) in the peripheral mononuclear cells collected from 73 CLL patients and CD19 positive B cells collected from 60 healthy controls, respectively. The expression of miR-155 in CLL patients was compared with the healthy controls, and the correlation of miR-155 expression with the clinical characteristics of CLL patients such as age, sex, Binet stage, cytogenetic and molecular genetic, as well as the relationship of miR-155 expression level with time to treatment (TTT) and overall survival (OS) was further analysed. The expression of miR-155 was significantly elevated in CLL patients compared with the healthy controls. Further analysis showed that miR-155 expression decreased in the patients with the mutated immunoglobulin heavy chian variable region (IGHV) as compared with the patients unmutated (P＜0.05), and its expression was significant higher in the IGHV-39 family (P＜0.05). Fluorescence in situ hybridization (FISH) showed that the expression of miR-155 increased in patients with P53 mmutation/deletion and ATM deletion (P＜0.05). However, OS and TTT were not different between the patients with high and low expression of miR-155. MiR-155 is increasingly expresses in CLL patients and correlates with poor prognosis, suggesting its important role in the genesis and progress of CLL.

Епштейна-Барр вірусної інфекції на рівень експресії miR -146a та miR -155 у пацієнтів з алергопатологією

Епштейна-Барр вірусної інфекції на рівень експресії miR -146a та miR -155 у пацієнтів з алергопатологією

Expression of MiR-155 in Tissue of Patients with Diffuse Large B-Cell Lymphoma and Its Effect on Cell Biological Characteristics

To investigate the expression of miR-155 in patients with diffuse large B-cell lymphoma (DLBCL), and to explore the effect of transfection of miR-155 inhibitor on the biological characteristics of DLBCL cells. A total of 76 patients with DLBCL treated in our hospital were selected from April 2013 to December 2017. In the same time, 40 cases of lymph node reactive hyperplasia (LNRH) were selected as control group. DB cells were cultured and divided into miR-155 inhibitor, negative control and blank groups. The expressions of miR-155 in DLBCL, negative and blank control groups were detected by using real-time PCR, the cell proliferation was detected by MTT assay, the apoptosis was detected by flow cytometry, and the cell migration and invasion were detected by Transwell assay. The relative expression level of miR-155 in tissues of DLBCL patients was significantly higher than that in tissne of controls (1.93±0.16 vs 1.01±0.09) (t=33.991, P=0.000). The expression level of miR-155 increased (P＜0.05) in DLBCL patients with LDH level abnormarity, BCL-2+, MUM1+, Ki-67≥50%, non-GC type, Ann Arbor stage III-IV, extranodal lesion number≥2 and IPI score 3-5. The relative expression level of miR-155 in the miR-155 inhibitor group was lower than that in the negative control group and the blank group (P＜0.05). The absorbance (A) values at 24, 48, 72 and 96 h of culture in the miR-155 inhibitor group were lower than those in the negative control group and the blank group (P＜0.05), while the apoptotic rate was higher than that in the negative control group and the blank group (P＜0.05). Both the migrating cells and invading cell number in the miR-155 inhibitor group were lower than those in the negative control group and the blank group (P＜0.05). The miR-155 highly expresses in DLBCL tissue, which relates with tumor malignancy and invasion progression. The specific inhibition of miR-155 expression in DB cells can reduce cell proliferation, accelerate cell apoptosis, and inhibit cell migration and invasion.

Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-α and CTLA4 genes in patients with Behcet’s disease

IntroductionMicroRNAs (miRNAs) are involved in the pathogenesis of inflammatory diseases. MiR-146 and miR-155 emerged as key regulators of the immune response. This study designed to analyze the miR-146a and miR-155 expression in patients with Behcet’s disease (BD) and investigated their association with the expression of tumor necrosis factor-alpha (TNF-α) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) genes. MethodologyIn a case-control study, 47 Iranian Azeri BD patients and 61 age- and sex matched healthy controls recruited to the study. Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA blood tubes by Ficoll density-gradient centrifugation. Genomic DNA samples of BD and healthy controls were extracted using the rapid genomic DNA extraction method from the peripheral blood collected in tubes containing EDTA. Total RNA was extracted from the PBMCs according to the TRIzol protocol. MiR-146a, miR-155, TNF-α and CTLA-4 expression were studied using real-time PCR. ResultsMiR-155 and TNF-α expression was significantly increased, whilst CTLA-4 expression was significantly decreased in the PBMCs of BD patients. There was no significant difference in the miR-146a expression rate between BD patients and controls. A positive correlation between miR-155 and TNF-α expression and negative correlation between miR-155 and CTLA-4 expression were observed. No significant association was observed between the expression of miR-155, miR-146a, TNF-α and CTLA-4 genes with BD activity. MiR-155 and miR-146a expression rate were significantly higher in patients with uveitis and phlebitis, respectively. Discussion and conclusionThe expression of miR-155 increased in BD and associated with upregulation of TNF-α and downregulation of CTLA-4 genes.

The Diagnostic Value of miR-155 Expression in the Serum of Patients with Breast Cancer According to Molecular Subtypes of Breast Cancer

Background: microRNAs (miRNAs) have been highlighted as potential circulating biomarkers and therapeutic targets for breast cancer (BC). miRNAs have emerged as an extremely promising new class of biomarkers. They have been demonstrated to be remarkably stable in human blood. miR-155 has more than 4 hundred predicted gene targets. The miR-155 plays an essential role in the pathogenesis of breast cancer. The aim of this study was to assess the diagnostic value of miR-155 expression in the serum of patients with breast cancer according to the molecular subtypes of BC. Methods: 90 samples were classified into different groups with respect to their immunohistochemical (IHC) characteristics: estrogen receptor (ER) positive and/or progesterone receptor (PR) positive group (Luminal A), human epidermal growth factor receptor2 (HER2) positive group (as Luminal B), and Triple negative group (TNBC). The complementary DNA (cDNA) was synthesized in line with the guidelines of the Kit Company. A real-time PCR method was performed as the expression assay. Results: A substantial difference was observed between the phrase standard of miR-155 in patients with the molecular subtypes of breast cancer. The subtypes of Luminal A, Luminal B, and TNBC showed respectively 6 fold, 7 fold, and 14 fold increased expression (P < 0.001). Receiver operating characteristic (ROC) analysis revealed that miR-155 had a considerable diagnostic accuracy for Luminal A with area under the curve (AUC) of 0.875 (sensitivity 100%, specificity 68.63%), for Luminal B with AUC of 0.886 (sensitivity 100%, specificity 62.75%), and for TNBC with AUC of 0.982 (sensitivity 100%, specificity 92.16%) Conclusions: The study found that increased mir-155 expression was significantly associated with BC. The study results showed the mir-155 expression has extremely high sensitivity and specificity for the diagnosis of subtypes of breast tumor. Therefore, checking the serum levels of miR-155 expression in patients with breast cancer may be helpful. Yet, more studies are required to investigate this relationship.

MiR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast

Background: Breast cancer (BC) is an illness affecting millions of women across the world. The transition from ductal carcinoma in situ to invasive ductal breast cancer is a crucial event in the progress that is still not well understood. microRNAs (miRNAs) have recently been documented to play an important role in cancer development. miRNAs have been discovered to control this critical transition. The miR-155 plays an essential role in the pathogenesis of breast cancer. miR-155 has been implicated in developing breast cancer. Objectives: This study aimed to investigate the expression of miR-155 in the serum of patients with breast cancer, according to clinical characteristics (DCIS and IDC) of breast cancer. Methods: 60 patients referring to hospitals in Ahvaz during 2012 and 2015 were divided into 2 groups according to clinical characteristics (DCIS and IDC). miRNA was extracted, and complementary DNA (cDNA) was synthesized in line with the guidelines of the Kit manufacturer . A real-time PCR method was performed as the expression assay. Results: The mean expression level of miR-155 in DCIS group was 6.45 ± 0.545. In addition, the mean expression level of miR-155 in serum of DCI group was 40.42 ± 0.742; the difference was statistically significant (P < 0.0001). Conclusions: Based on the results of this study, the serum level of miR-155 evidenced a statistically significant difference in invasive breast cancer (IDC) patients. The study results showed that checking the serum level of miR-155 expression in patients with invasive breast cancer (IDC) might be helpful.

Angiotensin receptor type 1 polymorphism A1166C is associated with altered AT1R and miR-155 expression in carotid plaque tissue and development of hypoechoic carotid plaques

Background and AimsThe principal biologic effects of the renin-angiotensin system are mediated by activation of the AT1R receptor. The microRNA miR-155 regulates AT1R expression, with both its, and AT1R's activity, linked to atherosclerosis. Target sites for miR-155 lie within the 3′ UTR of the human AT1R gene, and include the AT1R A1166C polymorphism. Thus far, only levels of circulating miR-155 have been investigated with respect to A1166C genotypes. We hypothesized that the A1166C polymorphism could correlate with different, ultra-sonographically defined plaque phenotypes, as well as with an altered expression of AT1R mRNA and protein in human carotid plaques (CP), and altered expression of miR-155 in patients with advanced atherosclerosis. MethodsOur study cohort comprised 411 patients with advanced carotid atherosclerosis (298 hyperechoic; 113 hypoechoic plaques). PCR analyses identified A1166C genotypes; quantitative real-time PCR determined AT1R and miR-155 expression levels, with AT1R protein expression evaluated by western blot. ResultsGenotypes containing the C allele bore a significant association with the hypoechoic plaque phenotype (adjusted OR 1.87, 95% CI 1.16–3.00, p = 0.01). The expression of AT1R mRNA and miR-155 were significantly up-regulated in the CPs of CC genotype carriers compared to the AA/AC genotypes (p = 0.032, p = 0.015, respectively). AT1R protein expression was also significantly higher for CC genotypes (p < 0.01). ConclusionOur results indicate that the AT1R A1166C polymorphism impacts an ultrasonographically-defined human plaque phenotype, with intra-plaque AT1R and miR-155 expression altered in advanced carotid atherosclerosis. Validation and replication of these data should contribute to an improved personalized therapy with which to prevent carotid atherosclerosis.

Role of miR-155 in invasion and metastasis of lung adenocarcinoma A549 cells

To investigate the role and mechanism of miR-155 in invasion and metastasis of lung adenocarcinoma A549 cells. Real-time PCR and fluorescence in situ hybridization were used to detect the miR-155 expression in patients' lung adenocarcinoma and adjacent tissue and lymph nodes. Scratch test and Transwell migration assay were used to assess the effect of miR-155 on the A549 cell migration and invasion capability. Bioinformatics software was used to predict the target genes of miR-155, and using luciferase to assay the target gene. Western blot and real-time PCR were performed to confirm the role of miR-155 expression in the regulation of target gene PTEN. The real-time quantitative PCR showed that the miR-155 expression levels in adjacent normal tissue, lung adenocarcinoma and metastatic lymph nodes were 4.1±0.5, 9.6±3.1 and 7.8±2.2, respectively. The in situ hybridization showed that the expression rates of miR-155 in the adjacent normal tissue, lung adenocarcinoma and metastatic lymph nodes were (23.2±15.3)%, (75.4±20.2)% and (60.4±25.1)%, respectively. The Scratch assay showed that the wound healing rates in the miR-155 mimics group, miR-155 mimics NC group, miR-155 inhibitor group and miR-155 inhibitor NC group at 24 h were (43.2±2.2)%, (21.3±4.2)%, (24.3±5.3)%, and (35.2±5.1)%, and that at 48 h were (75.2±4.5)%, (52.6±5.2)%, (39.4±4.2)%, and (51.5±4.3)%, respectively. Dual luciferase reporter gene assay showed that the value of the luciferase in the miR-155 mimics group co-transfected with PTEN 3'UTR-containing wild-type and mutant plasmids were 4.7±0.5 and 7.3±0.7, and the miR-155 mimics luciferase values of the control group co-transfected with PTEN 3'UTR-containing wild-type and mutant plasmids were 7.8±0.9 and 7.5±0.8, respectively. The real-time quantitative fluorescence PCR showed that the relative expression of PTEN protein in the miR-155 mimics group, miR-155 mimics control group, miR-155 mimics inhibitor group, and miR-155 inhibitor control group were 0.5±0.3, 1.0±0.1, 2.2±0.2 and 1.2±0.1, respectively. The Western blot assay detected that the relative expression of PTEN protein levels in the miR-155 mimics group, miR-155 mimics control group, miR-155 inhibitor group and miR-155 inhibitor control group were 0.4±0.1, 1.0±0.3, 2.8±0.2 and 1.4±0.1, respectively. The differences in PTEN mRNA and protein expressions of the four groups were statistically significant (P<0.05 for all). miR-155 may promote the invasion and metastasis of lung adenocarcinoma through reducing the target PTEN gene expression.

MicroRNA-155 Tissue Expression in Patients with Breast CanceratDr Haji Adam Malik Hospital, Medan

Background: MicroRNA (miRNA) is noncoding-RNA that comprises 18-22 nucleotides. miRNA binds its gene targets in the 3'-untranslated region (3'-UTR), causing direct degradation of mRNA and repressed translation of RNA. MicroRNA regulates various biological processes, including cell proliferation, apoptosis, cell growth, cell differentiation, and metabolism. Various changes have been identified miRNA expression in different types of cancers. This study aimed to describe the expression of miR-155 in patients with breast cancer tissue in Haji Adam Malik Hospital in Medan. Subjects and Method: This was a descriptive study. A total sample was 64 paraffin tissue blocks was taken from female patients with breast cancer at the surgical oncology unit, Haji Adam Malik Hospital in 2013-2014. RNA sample were isolated and checked using a spectrophotometer followed by cDNA synthesis. Then this sample was analyzed for miR-155 expression by using Real Time qPCR. Histopathological grade data were obtained from the medical record. Results: The miR-155 expression in the breast cancer patients is higher than that in the UniSp6 RNA Spike-in (internal controls). miR-155 expression was 29.64, 28.44, 29.22, in grade-I, grade-II, grade-III breast cancer, respectively. UniSp6 RNA Spike-in was 22.30, 22.89, 23.10, respectively in the control groups. Thus, increased of miR-155 expression was the highest in grade I breast cancer patients. Conclusion: Increased miR-155 expression can be used as a biomarker for early diagnosis and prognosis of breast cancer. Keywords: miRNA, miR-155, breast cancer. Correspondence : Henny Erina Saurmauli Ompusunggu. Department of Cellular and Molecular Biology, Faculty of Medicine, HKBP Nommensen University, Medan. Email: ompusunggu.henny@gmail.com Indonesian Journal of Medicine (2016), 1(1): 20-25 https://doi.org/10.26911/theijmed.2016.01.01.03